Concepedia

Christopher Littlefield

CL

Statistics

Publications

2

Citations

249

H-Index

2

Active since

2020

Affiliations

Scholar Rock (United States)(Current)

Christopher Littlefield is an author at Scholar Rock (United States) specializing in checkpoint inhibitor therapy, tumor microenvironment modulation, and cancer immunology.

Publications per year

2020–2024

2

Publications

2

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

Constance J. Martin, Abhishek Datta, Christopher Littlefield et al. · Science Translational Medicine · 2020 · 231 citations

, , +14

An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis

Justin Jackson, Frederick C. Streich, Ajai Pal et al. · Science Signaling · 2024 · 18 citations

, , +17

1–2 of 2